

ProBioGen AG Appoints Wiltrud Treffenfeldt to the Supervisory Board

Berlin, October 2005 – ProBioGen AG has named Professor Dr. Wiltrud Treffenfeldt as a new member of the supervisory board. The annual general assembly of the Berlin-based company unanimously appointed her for the next four years. She is Director for Bioprocess Development at The Dow Chemical Company, USA. Wiltrud Treffenfeldt is responsible for the design and implementation of strategies in the areas of human and animal health at Dow and Dow AgroSciences with the goal of creating sustainable value within the biotechnology sector.

As an internationally renowned expert in the industry, Dr. Treffenfeldt increases the expertise of ProBioGen's supervisory board through her extensive experience in red and white biotechnology. She has excellent contacts to industry, science, and research. Dr. Treffenfeldt holds many advisory positions in research institutes; she has been honorary professor at the University of Hannover since 1995, was a member of the executive board of the European Federation of Biotechnology from 2001 to 2002, and has been a consultant for the German Federal Ministry of Education and Research (BMBF) for five years. Dr. Treffenfeldt will be able to effectively leverage her experience to further develop Europe's relatively young biotechnology industry.

Michael Schlenk, CEO of ProBioGen AG, emphasizes that the company will greatly benefit from Dr. Treffenfeldt's contribution to the supervisory board. *"In the next twelve months, we will bring two newly developed mammalian cell technologies onto the market. Dr. Treffenfeldt's network and contacts will significantly help us increase the value of our new advancements,"* Schlenk explains.

Dr. Wiltrud Treffenfeldt expects her role as a member of the company's supervisory board to be very positive. *"Due to my longstanding contacts with ProBioGen's scientists and managers, I have seen how this very innovative and creative company has consistently been able to balance both technological and commercial objectives. I am looking forward to supporting ProBioGen on its path for future success,"* says the new supervisory board member.

The expansion of the supervisory board reflects the outstanding advancement of the innovative Berlin-based company, which has consistently expanded from German markets to international ones. In past years, ProBioGen has performed consistently as a first-class provider for mammalian cell based technology.

About ProBioGen AG

ProBioGen AG is a specialist for cell line design, viral vectors, and the manufacture of glycoproteins for the biopharmaceutical industry. The biotechnology company is headquartered in Berlin and was founded in 1994 as a spin-off from the Charité University Hospital. Its range of products and services includes the design of novel cell lines from primary tissue, the development of highly productive mammalian cell lines, as well as the manufacture of glycoproteins for clinical studies. ProBioGen possesses the manufacturing authorization for pharmaceutically usable active substances for testing in clinical studies and meets the quality standards recommended by the EU (EMA) and the FDA. A certified cGMP multipurpose facility is available for the contract production of biopharmaceutical active substances. The company combines the know-how of molecular biology scientists with the experience of experts in cell culture technology and process engineering. ProBioGen accompanies its clients through all stages, from the development of product candidates to the clinical testing phase.

Additional Information and Photo Material:

ProBioGen AG
Michael Schlenk
Goethestraße 54
13068 Berlin/Weissensee
Tel.: +49 (30) 924 00 60
Fax: +49 (30) 924 00 619
e-mail: michael.schlenk@probiogen.de
www.probiogen.de